Empactful Capital

Empactful Capital

Empactful Capital operates from Doylestown, Pennsylvania, deploying venture capital on behalf of a partnership group anchored by managing partners Sal DeTrane and Steven Mason. The firm's thesis reflects the founders' own histories: each previously built and exited a digital health company, and they now commit capital and operating time to founders engineering technology for whole-person care. The website cites 400 years of combined operating experience across the partnership and advisory network. Strategy concentrates on early-stage and growth venture investing in teams that create technology targeting health systems, health plans, and employers. The portfolio reveals a bias toward care coordination, behavioral health infrastructure, and analytics platforms — asset classes where data interoperability and clinical workflow integration determine enterprise contracting velocity. Confirmed positions include ThoroughCare, an independent-practice care coordination platform; Reema Health, which uses community guides to address social determinants of health; and Reciprocity Health, which designs cash-incentive programs to lift adherence rates. The firm co-invests across the United States and will also participate in deals involving international expansion. Eight portfolio companies have recorded exits, including Owl (acquired by Neuroflow in 2024) and Veda (acquired by H1 in 2025). A general partnership structure includes Mark Silverman, Arnold Silverman, and Doug Williams alongside the managing partners, supported by a roster of operating partners with tenures at Change Healthcare, Optum, and Tufts Medicine. Empactful Capital also maintains Empactful Advisors, a separate entity run by managing partners Jimmy Leppert and Justin Wasserman, indicating a parallel advisory business alongside the venture fund. May 2025: Portfolio company Veda was acquired by H1 (per the firm, May 2025). The firm has not publicly disclosed aggregate deployment, AUM, or current fund size. Empactful Capital runs a lean, operator-dense general partnership rather than a multi-strategy platform. The absence of disclosed limited partner identity or institutional fund-of-funds relationships creates a sourcing model that likely depends on the general partners' personal networks in the digital health C-suite — a structure that concentrates governance risk in a small senior team but can move faster on founder diligence than a committee-heavy institutional venture firm.